SI3484888T1 - Trdne oblike inhibitorja ttk - Google Patents

Trdne oblike inhibitorja ttk

Info

Publication number
SI3484888T1
SI3484888T1 SI201731352T SI201731352T SI3484888T1 SI 3484888 T1 SI3484888 T1 SI 3484888T1 SI 201731352 T SI201731352 T SI 201731352T SI 201731352 T SI201731352 T SI 201731352T SI 3484888 T1 SI3484888 T1 SI 3484888T1
Authority
SI
Slovenia
Prior art keywords
solid forms
ttk inhibitor
ttk
inhibitor
solid
Prior art date
Application number
SI201731352T
Other languages
English (en)
Slovenian (sl)
Inventor
Sze-Wan Li
Heinz W. Pauls
Peter Brent Sampson
Original Assignee
University Health Network
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Health Network filed Critical University Health Network
Publication of SI3484888T1 publication Critical patent/SI3484888T1/sl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C30CRYSTAL GROWTH
    • C30BSINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B29/00Single crystals or homogeneous polycrystalline material with defined structure characterised by the material or by their shape
    • C30B29/54Organic compounds
    • C30B29/58Macromolecular compounds
    • CCHEMISTRY; METALLURGY
    • C30CRYSTAL GROWTH
    • C30BSINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B7/00Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions
    • C30B7/02Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions by evaporation of the solvent
    • CCHEMISTRY; METALLURGY
    • C30CRYSTAL GROWTH
    • C30BSINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B7/00Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions
    • C30B7/14Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions the crystallising materials being formed by chemical reactions in the solution
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Materials Engineering (AREA)
  • Metallurgy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SI201731352T 2016-07-18 2017-07-13 Trdne oblike inhibitorja ttk SI3484888T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662363424P 2016-07-18 2016-07-18
PCT/CA2017/050848 WO2018014116A1 (en) 2016-07-18 2017-07-13 Solid forms of ttk inhibitor
EP17830139.6A EP3484888B1 (en) 2016-07-18 2017-07-13 Solid forms of ttk inhibitor

Publications (1)

Publication Number Publication Date
SI3484888T1 true SI3484888T1 (sl) 2023-07-31

Family

ID=60991755

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201731352T SI3484888T1 (sl) 2016-07-18 2017-07-13 Trdne oblike inhibitorja ttk

Country Status (25)

Country Link
US (3) US10584130B2 (https=)
EP (1) EP3484888B1 (https=)
JP (2) JP6961675B2 (https=)
KR (2) KR102700233B1 (https=)
CN (2) CN115093416B (https=)
AU (2) AU2017299850B2 (https=)
BR (1) BR112019000813A2 (https=)
DK (1) DK3484888T3 (https=)
ES (1) ES2945108T3 (https=)
FI (1) FI3484888T5 (https=)
HR (1) HRP20230481T1 (https=)
HU (1) HUE061872T2 (https=)
IL (1) IL264173B2 (https=)
LT (1) LT3484888T (https=)
MA (1) MA45691A (https=)
MX (2) MX385289B (https=)
PL (1) PL3484888T3 (https=)
PT (1) PT3484888T (https=)
RS (1) RS64210B1 (https=)
RU (2) RU2753905C2 (https=)
SG (2) SG10202103332UA (https=)
SI (1) SI3484888T1 (https=)
SM (1) SMT202300156T1 (https=)
TW (2) TWI745400B (https=)
WO (1) WO2018014116A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017299850B2 (en) 2016-07-18 2021-05-27 University Health Network Solid forms of TTK inhibitor
KR20240175121A (ko) 2023-06-12 2024-12-19 한국재료연구원 희토류 산화물을 이용한 입계확산물질의 제조방법 및 이를 이용한 R-Fe-B계 영구자석의 제조방법

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2438092C (en) 2001-02-21 2011-08-09 Chiron Corporation Ttk in diagnosis and as a therapeutic target in cancer
ATE482213T1 (de) * 2004-11-04 2010-10-15 Vertex Pharma Als inhibitoren von proteinkinasen geeignete pyrazoloä1,5-aüpyrimidine
TW201107329A (en) * 2009-07-30 2011-03-01 Oncotherapy Science Inc Fused imidazole derivative having ttk inhibitory action
TWI541243B (zh) * 2010-09-10 2016-07-11 拜耳知識產權公司 經取代咪唑并嗒
CN103415518A (zh) * 2010-12-17 2013-11-27 拜耳知识产权有限责任公司 在过度增殖性病症的治疗中用作mps-1和tkk抑制剂的咪唑并吡嗪
US9573954B2 (en) * 2012-11-16 2017-02-21 University Health Network Pyrazolopyrimidine compounds
JP6095857B2 (ja) * 2013-11-15 2017-03-15 ユニバーシティ・ヘルス・ネットワーク ピラゾロピリミジン化合物
AU2017299850B2 (en) 2016-07-18 2021-05-27 University Health Network Solid forms of TTK inhibitor

Also Published As

Publication number Publication date
JP7263473B2 (ja) 2023-04-24
PL3484888T3 (pl) 2023-06-26
MA45691A (fr) 2019-05-22
HRP20230481T1 (hr) 2023-07-21
CN115093416B (zh) 2024-04-12
AU2017299850A1 (en) 2019-01-24
TW201803876A (zh) 2018-02-01
JP2019521155A (ja) 2019-07-25
IL264173B1 (en) 2025-01-01
US10584130B2 (en) 2020-03-10
ES2945108T3 (es) 2023-06-28
RU2019101109A3 (https=) 2021-02-05
BR112019000813A2 (pt) 2019-04-30
CN109476667B (zh) 2022-06-28
FI3484888T5 (fi) 2024-02-26
HUE061872T2 (hu) 2023-08-28
AU2021221447A1 (en) 2021-10-07
MX2021008658A (es) 2021-08-19
EP3484888B1 (en) 2023-02-22
PT3484888T (pt) 2023-05-26
AU2021221447B2 (en) 2023-09-21
WO2018014116A1 (en) 2018-01-25
NZ749844A (en) 2024-03-22
US11878980B2 (en) 2024-01-23
CN109476667A (zh) 2019-03-15
KR102537088B1 (ko) 2023-05-25
FI3484888T3 (fi) 2023-05-03
SG10202103332UA (en) 2021-05-28
CN115093416A (zh) 2022-09-23
TW202202507A (zh) 2022-01-16
EP3484888A4 (en) 2020-01-08
TWI745400B (zh) 2021-11-11
AU2017299850A8 (en) 2019-03-21
EP3484888A1 (en) 2019-05-22
IL264173A (en) 2019-02-28
DK3484888T3 (da) 2023-05-30
US20220089601A1 (en) 2022-03-24
IL264173B2 (en) 2025-05-01
KR20230074839A (ko) 2023-05-31
RU2753905C2 (ru) 2021-08-24
JP2022001598A (ja) 2022-01-06
RU2021124795A (ru) 2021-09-14
RS64210B1 (sr) 2023-06-30
MX2019000744A (es) 2019-05-02
RU2019101109A (ru) 2020-08-18
JP6961675B2 (ja) 2021-11-05
CA3030230A1 (en) 2018-01-25
US20190292193A1 (en) 2019-09-26
MX385289B (es) 2025-03-18
SMT202300156T1 (it) 2023-07-20
US11104681B2 (en) 2021-08-31
KR102700233B1 (ko) 2024-08-28
KR20190029601A (ko) 2019-03-20
SG11201900113UA (en) 2019-02-27
US20200270259A1 (en) 2020-08-27
LT3484888T (lt) 2023-06-12
AU2017299850B2 (en) 2021-05-27
TWI824313B (zh) 2023-12-01

Similar Documents

Publication Publication Date Title
IL259794A (en) Bicyclic inhibitors for pad4
ZA201803436B (en) Inhibitors of cxcr2
IL252756A0 (en) solid forms of ask1 inhibitor
IL251584B (en) Dihydropyrrolopyridines ror–gamma inhibitors
ZA201604272B (en) Inhibitors of glutaminase
IL246902B (en) Dihydropyrrolopyridine ror–gamma inhibitors
IL259796A (en) Aza-benzimidazole inhibitors of pad4
IL279949A (en) Heterocyclic MCT4 inhibitors
IL257026A (en) Solid state forms of eluxadoline
IL257061A (en) Inhibitors of ezh2
EP3405477C0 (en) TRANSGLUTAMINASE INHIBITORS
GB201521059D0 (en) Inhibitors of metallo-beta-lactamases
GB201708457D0 (en) Inhibitors of metallo-beta-lactamases
IL265628A (en) Solid state forms of valbenazine
ZA201706282B (en) Solid forms of menaquinols
IL264173A (en) Solid forms of ttk inhibitor
GB201708451D0 (en) Inhibitors of metallo-beta-lactamases